Synthetic biology is in its infancy, but the science of programming DNA could lead to a manufacturing revolution akin to the internet revolution of a generation ago. Join Barron's senior managing editor Lauren R. Rublin, Barron's Associate Editor Andrew Bary, and Dr. Jason Kelly, co-founder and CEO of Ginkgo Bioworks, to learn more about investing in the future of this exciting technology.

Wed, Aug 18, 2021 · 3:00 PM Eastern Time (US & Canada) (GMT -4:00)
Lauren Rublin
Senior Managing Editor
Lauren R. Rublin is the senior managing editor at Barron's, overseeing Roundtables and Special Projects. She previously worked in book publishing, and at Fairchild Publications and Time Inc.
Andrew Bary
Associate Editor, Barron's
Andrew Bary is an associate editor at Barron's, covering a wide range of financial and investment topics. He joined Barron's in 1992 as a reporter and has worked for Barron's parent, Dow Jones, for more than three decades.
Dr. Jason Kelly
Co-Founder and CEO, Ginkgo Bioworks
Dr. Jason Kelly is the co-founder and CEO of Ginkgo Bioworks, a synthetic biology company that programs cells for customers in the chemical, pharmaceutical, food and energy industries. The company has been listed for the past three years on CNBC's Disruptor 50 List of fast-growing companies. Jason earned B.S. degrees in Chemical Engineering and Biology and a PhD in Biological Engineering at MIT.